자궁근종 치료 기기 시장 : 제품 유형, 기술, 최종 사용자, 유통 채널별 - 세계 시장 예측(2026-2032년)

The Uterine Fibroid Treatment Device Market is projected to grow by USD 14.07 billion at a CAGR of 9.36% by 2032.

Uterine Fibroid Treatment Device Market Overview

Uterine fibroid treatment devices are evolving from a procedure-centric category into a women's health technology segment focused on uterus preservation, faster recovery, lower complication risk, and durable symptom control. Uterine fibroids are among the most common benign tumors of the uterus, with epidemiologic studies widely reporting cumulative prevalence approaching 70% to 80% by age 50; a clinically significant share of patients experience heavy menstrual bleeding, pelvic pain, anemia, infertility, recurrent pregnancy loss, or pregnancy complications.

Demand is supported by the shift from open hysterectomy and abdominal myomectomy toward minimally invasive uterine fibroid treatment options, including transcervical radiofrequency ablation, laparoscopic radiofrequency ablation, hysteroscopic tissue removal systems, uterine artery embolization devices, MRI-guided focused ultrasound, and high-intensity focused ultrasound. Hospitals, ambulatory surgery centers, interventional radiology suites, and gynecology practices are evaluating devices based on clinical evidence, reimbursement access, capital requirements, physician training, patient preference, recovery profile, and long-term reintervention rates.

Transformative Shifts in the Treatment Landscape

The uterine fibroid treatment device landscape is being reshaped by patient demand for uterus-sparing procedures and by clinician interest in technologies that reduce length of stay, blood loss, adhesions, and recovery time. Treatment decision-making is increasingly individualized, with device selection influenced by fibroid size, number, location, symptoms, age, fertility goals, comorbidities, and patient tolerance for repeat intervention.

Another major shift is the convergence of imaging, energy delivery, and outpatient care. Real-time ultrasound guidance, MRI-guided targeting, advanced hysteroscopic visualization, and controlled ablation platforms are expanding procedural precision. At the same time, value-based healthcare is pressuring device manufacturers to demonstrate durable outcomes, predictable workflow, lower total cost of care, and measurable improvement in health-related quality of life.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is beginning to influence the uterine fibroid treatment device market through imaging interpretation, procedural planning, risk stratification, and workflow automation. AI-assisted ultrasound and MRI analytics can help identify fibroid volume, vascularity, location, and treatment eligibility, supporting more consistent preoperative assessment and shared decision-making.

Over time, AI can strengthen patient selection for radiofrequency ablation, focused ultrasound, embolization, and surgical approaches by comparing imaging data with outcomes registries and real-world evidence. The cumulative impact is expected to include improved triage, fewer inappropriate procedures, better prediction of symptom relief, and more efficient use of operating rooms and interventional suites, provided that algorithms are clinically validated across diverse populations and integrated under strong data governance, cybersecurity, and regulatory oversight.

Key Regional Insights Across Global Markets

North America remains a leading region for uterine fibroid treatment devices due to established gynecology and interventional radiology infrastructure, availability of cleared minimally invasive technologies, strong diagnostic pathways, and a large diagnosed patient population. The United States and Canada benefit from advanced imaging access, procedure training networks, and patient awareness of alternatives to hysterectomy, although payer coverage and site-of-care economics continue to shape adoption. Europe follows with strong hospital-based adoption, evidence-driven procurement, and country-specific reimbursement dynamics, while the European Union's medical device regulatory framework increases the importance of clinical data, post-market surveillance, risk management, and manufacturer quality systems.

Asia-Pacific is expanding as China, India, Japan, South Korea, and Australia improve access to advanced imaging, laparoscopic surgery, interventional radiology, and noninvasive focused ultrasound. The region also reflects a substantial underlying fibroid burden and growing demand for fertility-preserving care. Latin America is gaining momentum through private hospital networks in Brazil and Mexico, although affordability, specialist availability, and reimbursement variability influence adoption. The Middle East, led by advanced hospital systems in GCC markets, is investing in women's health, medical tourism, and image-guided procedures, while Africa shows emerging opportunity where urban specialty centers are addressing underdiagnosis, anemia burden, and limited access to minimally invasive fibroid care.

Key Group Insights for Strategic Expansion

ASEAN markets are characterized by rising awareness of abnormal uterine bleeding, improving access to gynecologic endoscopy, and expanding private healthcare participation, with Singapore, Malaysia, Thailand, Indonesia, Vietnam, and the Philippines advancing at different speeds based on insurance coverage, hospital infrastructure, and specialist availability. GCC countries are adopting premium hospital technologies and medical tourism strategies, supporting demand for image-guided and minimally invasive uterine fibroid treatment systems in high-acuity women's health centers.

The European Union is shaped by rigorous clinical evaluation, increasingly coordinated health technology assessment practices, and procurement scrutiny, creating advantages for devices with strong safety, effectiveness, and outcomes data. BRICS countries represent scale, growing middle-class demand, and expanding hospital capacity, but market entry requires localized pricing, training, service support, and navigation of heterogeneous regulatory systems. G7 countries offer mature reimbursement, advanced clinical research ecosystems, and established minimally invasive procedure pathways, while NATO-aligned healthcare systems place additional emphasis on resilient supply chains, regulatory reliability, continuity of medical device access, and adoption of proven technologies.

Key Country Insights for Uterine Fibroid Devices

The United States leads in commercial availability, physician training, clinical research activity, and adoption of cleared minimally invasive fibroid devices, while Canada balances advanced care access with provincial reimbursement and hospital budget pathways. Mexico and Brazil show growing demand in private healthcare networks, supported by urban specialty centers, increasing use of gynecologic endoscopy, and a rising focus on women's health outcomes. In Europe, the United Kingdom, Germany, France, Italy, and Spain support adoption through hospital gynecology, interventional radiology, imaging infrastructure, and ambulatory surgery capabilities, while Russia remains influenced by public-sector procurement, regional care disparities, and access differences between major urban centers and underserved areas.

China and India offer large patient populations, increasing investment in hospital capacity, and expanding domestic medical technology capability, with adoption influenced by affordability, physician training, and regional infrastructure differences. Japan prioritizes safety, quality systems, and evidence-based introduction of advanced devices, while Australia benefits from strong specialty access, diagnostic pathways, and established minimally invasive care models. South Korea combines advanced imaging infrastructure, digitally enabled hospitals, and rapid uptake of precision medical technologies, supporting procedural innovation in gynecology and interventional care.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinically differentiated uterine fibroid treatment devices that address high-burden symptoms such as heavy menstrual bleeding, pelvic pressure, anemia, pain, and fertility-related concerns. Evidence packages should include validated symptom scores, quality-of-life measures, recovery time, adverse events, return-to-activity timelines, pregnancy-related data where applicable, and reintervention rates.

Commercial success will depend on physician education, procedure standardization, reimbursement support, and patient-facing education that clearly explains alternatives to hysterectomy and myomectomy. Device developers should also invest in partnerships with imaging providers, women's health clinics, interventional radiology teams, and ambulatory surgery centers while designing region-specific pricing, training, maintenance, and service models for emerging markets.

Research Methodology and Evidence Framework

This executive summary is developed using a structured secondary research framework and evidence-based market intelligence methodology. Sources include peer-reviewed gynecology and interventional radiology literature, clinical practice guidance from recognized medical societies, regulatory databases, reimbursement information, hospital procurement trends, product documentation, and epidemiologic evidence on uterine fibroid prevalence, symptom burden, and treatment outcomes.

Insights are synthesized through triangulation across clinical evidence, technology adoption patterns, regional healthcare infrastructure, regulatory requirements, reimbursement dynamics, and procedure workflow considerations. The methodology emphasizes verified facts, consistency across credible sources, exclusion of unsupported projections, and practical interpretation for strategic planning in the uterine fibroid treatment device market.

Conclusion: Outlook for Fibroid Treatment Devices

The uterine fibroid treatment device market is positioned for continued strategic importance as patients and clinicians seek effective, uterus-sparing, and minimally invasive alternatives to conventional surgery. The strongest opportunities are emerging where imaging precision, energy-based treatment, outpatient workflow, and evidence-based patient selection converge.

Organizations that combine clinical credibility, regulatory discipline, physician training, reimbursement readiness, and accessible patient education will be best placed to meet demand. As artificial intelligence, advanced imaging, and value-based care mature, the market will increasingly reward technologies that deliver measurable symptom relief, safety, procedural efficiency, and long-term patient-centered outcomes.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Uterine Fibroid Treatment Device Market, by Product Type

• 7.1. High Intensity Focused Ultrasound
• 7.2. Hysterectomy
  • 7.2.1. Abdominal
  • 7.2.2. Laparoscopic
  • 7.2.3. Vaginal
• 7.3. Myomectomy
  • 7.3.1. Hysteroscopic
  • 7.3.2. Laparoscopic
  • 7.3.3. Open
• 7.4. Radiofrequency Ablation
• 7.5. Uterine Artery Embolization

8. Uterine Fibroid Treatment Device Market, by Technology

• 8.1. Cryoablation
• 8.2. High Intensity Focused Ultrasound
• 8.3. Microwave Ablation
• 8.4. Radiofrequency Ablation

9. Uterine Fibroid Treatment Device Market, by End User

• 9.1. Ambulatory Surgical Centers
• 9.2. Clinics
• 9.3. Hospitals
• 9.4. Specialized Fibroid Centers

10. Uterine Fibroid Treatment Device Market, by Distribution Channel

• 10.1. Offline
• 10.2. Online

11. Uterine Fibroid Treatment Device Market, by Region

• 11.1. Asia-Pacific
• 11.2. North America
• 11.3. Latin America
• 11.4. Europe
• 11.5. Middle East
• 11.6. Africa

12. Uterine Fibroid Treatment Device Market, by Group

• 12.1. ASEAN
• 12.2. GCC
• 12.3. European Union
• 12.4. BRICS
• 12.5. G7
• 12.6. NATO

13. Uterine Fibroid Treatment Device Market, by Country

• 13.1. United States
• 13.2. Canada
• 13.3. Mexico
• 13.4. Brazil
• 13.5. United Kingdom
• 13.6. Germany
• 13.7. France
• 13.8. Russia
• 13.9. Italy
• 13.10. Spain
• 13.11. China
• 13.12. India
• 13.13. Japan
• 13.14. Australia
• 13.15. South Korea

14. Competitive Landscape

• 14.1. Market Concentration Analysis, 2025
  • 14.1.1. Concentration Ratio (CR)
  • 14.1.2. Herfindahl Hirschman Index (HHI)
• 14.2. Recent Developments & Impact Analysis, 2025
• 14.3. Product Portfolio Analysis, 2025
• 14.4. Benchmarking Analysis, 2025

15. Company Profiles

• 15.1. Abbott Laboratories
• 15.2. Acessa Health Inc.
• 15.3. AngioDynamics, Inc.
• 15.4. Boston Scientific Corporation
• 15.5. Cook Group Incorporated
• 15.6. CooperSurgical, Inc.
• 15.7. Gynesonics, Inc.
• 15.8. Hologic, Inc.
• 15.9. INSIGHTEC Ltd.
• 15.10. Karl Storz SE & Co. KG
• 15.11. Medtronic plc
• 15.12. Merit Medical Systems, Inc.
• 15.13. Minerva Surgical, Inc.
• 15.14. Olympus Corporation
• 15.15. Profound Medical Corp.
• 15.16. Richard Wolf GmbH
• 15.17. SonaCare Medical, LLC
• 15.18. Varian Medical Systems, Inc.